AtaiBeckley Inc.
ATAINasdaq
$7.22
↑ +1.0%Jul 17 close · end-of-day
Price
1Y↑ +167.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.6B
Enterprise Value
$1.8B
P/E
—
P/S
400.0
P/B
8.2
EV/EBITDA
—
PEG
—
FCF Yield
-6.3%
Dividend Yield
—
Revenue (TTM)
$4.1M
Net Income (TTM)
-$660.0M
Free Cash Flow (TTM)
-$103.6M
Gross Margin
—
Operating Margin
-15751.1%
Net Margin
-16142.0%
ROE
-332.2%
ROIC
-157.8%
Debt / Equity
0.8
Net Cash
-$123.7M
Return 1Y
+158.8%
Company profile
Atai Life Sciences N.V. operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD)
- CEO
- Florian Brand
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Website
- atai.life
Earnings
ATAI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$954,000.00↓ -38.6%
Diluted EPS-$0.08↓ -46.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | $308,000.00 | $4.1M |
| Gross profit | — | — |
| Operating income | -$102.7M | -$644.1M |
| Net income | -$149.3M | -$660.0M |
| Diluted EPS | -$0.93 | -$2.91 |
| Operating cash flow | -$82.4M | -$102.7M |
| Free cash flow | -$82.4M | -$103.6M |
| Gross margin | — | — |
| Operating margin | -33341.2% | -15751.1% |
| Net margin | -48464.0% | -16142.0% |
| Line item | Q1 '25 | Q1 '26 |
|---|---|---|
| Revenue | $1.6M | $954,000.00 |
| Gross profit | — | — |
| Operating income | -$20.4M | -$30.9M |
| Net income | -$26.4M | -$29.8M |
| Diluted EPS | -$0.15 | -$0.08 |
| Operating cash flow | -$17.8M | -$21.1M |
| Free cash flow | -$18.1M | -$21.1M |
| Gross margin | — | — |
| Operating margin | -1310.0% | -3239.1% |
| Net margin | -1699.7% | -3121.8% |
Company news
Jul 17, 2026
- 3d agoAtaiBeckley acquisition highlights growing Big Pharma interest in psychedelicsproactiveinvestors.com
- 3d agoAtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valuedfinance.yahoo.com
- 3d agoEli Lilly's $3.8bn psychedelics bet is built on British scienceproactiveinvestors.com
- 3d agoAtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lillyfinance.yahoo.com
Jul 16, 2026
- 4d agoEli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeoverfinance.yahoo.com
- 4d agoAtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyoutfinance.yahoo.com
- 4d agoEli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion to Expand Neuroscience Pipelinefinance.yahoo.com
- 4d agoAtaiBeckley Stock Is Soaring 31% as Eli Lilly Agrees to Buy Psychedelic Drugmakerfinance.yahoo.com
- 4d agoEli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapyfinance.yahoo.com
- 4d agoUnitedHealth rallies premarket while chip stocks retreat; TSMC’s record earningsfinance.yahoo.com
- 4d agoAtaiBeckley to be acquired by Eli Lilly in deal valued at up to $3.8 billionproactiveinvestors.com
- 4d agoNasdaq slides as chip selloff drags Wall Street lowerproactiveinvestors.com
- 4d agoWhy Psychedelic stocks are surging todayfinance.yahoo.com
- 4d agoEli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billionwsj.com
- 4d agoLilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-11-05 | Feilding-Mellen Cosmo | Award | 7,702,990 | — | — | filing |
| 2025-09-30 | Apeiron Investment Group Ltd. | C | 2,367,200 | — | — | filing |
| 2025-08-14 | Apeiron Investment Group Ltd. | Buy | 8,675,799 | $2.19 | $19.0M | filing |
Latest 3 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.